PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10192824-2	1999	Physostigmine (PHYSO), a reversible cholinesterase inhibitor, was administered to normal women and men at a dose that elevated plasma ACTH1-39, cortisol, and arginine vasopressin (AVP) concentrations but produced few or no side effects.	Physostigmine	0-13	arginine vasopressin	Homo sapiens	167-178	
10822901-0	2000	Effect of aging on the arginine-vasopressin response to physostigmine and angiotensin II in normal men.	Physostigmine	56-69	arginine vasopressin	Homo sapiens	32-43	
10822901-2	2000	Both drugs induced significant increments in plasma AVP levels in the youngest group, with mean peak levels 4.8 times higher than baseline at 20 minutes after the beginning of physostigmine infusion and 1.5 times higher than baseline at 60 minutes after the beginning of ANG II infusion.	Physostigmine	176-189	arginine vasopressin	Homo sapiens	52-55	
10822901-5	2000	However, the AVP increases induced by physostigmine (mean peak was 9 times higher than baseline) and ANG II (mean peak was 2.2 times higher than baseline) were significantly higher in the oldest group than in the other groups.	Physostigmine	38-51	arginine vasopressin	Homo sapiens	13-16	
9642034-6	1998	On the other hand, the anticholinesterase, physostigmine, potentiated both the vasopressin-induced tonic and spontaneous contractions.	Physostigmine	43-56	arginine vasopressin	Homo sapiens	79-90	
9447863-2	1998	Cholinergic stimulation of the hypothalamic-pituitary-adrenal axis and adrenal medulla by physostigmine enhances secretion of arginine vasopressin, epinephrine, and norepinephrine.	Physostigmine	90-103	arginine vasopressin	Homo sapiens	135-146	
8562665-0	1995	Oral physostigmine in Alzheimer"s disease: effects on norepinephrine and vasopressin in cerebrospinal fluid and plasma.	Physostigmine	5-18	arginine vasopressin	Homo sapiens	73-84	
8562665-2	1995	In this study, we explored in persons with Alzheimer"s disease (AD) the effects of an acute dose of physostigmine in patients receiving chronic physostigmine treatment on the activity of the cholinergically regulated noradrenergic and arginine vasopressin (AVP) systems.	Physostigmine	100-113	arginine vasopressin	Homo sapiens	244-255	
8562665-2	1995	In this study, we explored in persons with Alzheimer"s disease (AD) the effects of an acute dose of physostigmine in patients receiving chronic physostigmine treatment on the activity of the cholinergically regulated noradrenergic and arginine vasopressin (AVP) systems.	Physostigmine	144-157	arginine vasopressin	Homo sapiens	244-255	
2525015-2	1989	Physostigmine promptly increased plasma arginine vasopressin (tenfold), beta-endorphin (twofold to threefold) and epinephrine (threefold) levels in elderly control subjects.	Physostigmine	0-13	arginine vasopressin	Homo sapiens	49-60	
11927192-1	2002	We previously demonstrated that the reversible cholinesterase inhibitor, physostigmine (PHYSO), administered to normal young adult women and men (average age 35 years) at a dose that produced few or no side effects, resulted in a sex difference (sexual diergism) in hypothalamo-pituitary-adrenal cortical (HPA) axis responses: Plasma ACTH(1-39), cortisol, and arginine vasopressin (AVP) concentrations increased to a significantly greater extent in the men than in the women.	Physostigmine	73-86	arginine vasopressin	Homo sapiens	369-380